Brain scans reveal new clues to Depression's inner workings

NCT ID NCT05630963

Recruiting now Knowledge-focused Sponsor: Mclean Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates how a brain chemical system called nociceptin/orphanin FQ relates to major depression. Researchers will use PET and MRI scans, along with behavioral tasks, to examine brain activity and decision-making in people with current or past depression. The goal is to better understand depression and identify potential new treatment targets.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help identify new targets for treating depression beyond current medications.
What could go wrong: This is an observational study, not a treatment trial. It is early-stage and may not lead to direct clinical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

McLean Hospital
RECRUITING

Belmont, Massachusetts, 02478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.